Ribo Discloses Positive Data from Vortosiran Phase 2a Trial – World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

2026-07-22 – Press Releases – www.prnewswire.com

SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…

Read the full article here.